Javascript must be enabled to continue!
PROSTATIC HYPERPLASIA (BPH);
View through CrossRef
Objectives: To determine the efficacy of tamsulosin with and without tolterodine in patients having benign prostatic hyperplasia (BPH) with irritative (overactive bladder) symptoms. Study Design: Randomized clinical trial. Setting: Department of Urology and Kidney Transplantation, Sheikh Zayed Hospital Lahore. Period: Six months from July to Dec 2017. Patients and Methods: Sixty patients of BPH had irritative (overactive bladder) & obstructive presentation were recruited. Patients were categorized in two groups and were compared for efficacy according to international prostatic symptom scoring while the data analyzed in SPSS 16. Results: Patients with BPH having irritative (overactive bladder) symptoms, after receiving Tamsulosin with Tolterodine, 76.60% (23/30) of patients reported symptomatic improvement whereas only 40.00 % (12/30) of subjects improved with tamsulosine only. Rate of improvement was observed to be higher in individuals with tamsulosine with tolterodine (Group B) than group A (includes tamsulosin only) with statistical significance) chi-square = 8.297; p=0.004). Conclusion: Efficacy of tamsulosin with tolterodine is higher than tamsulosin alone in subjects with BPH had irritative (overactive bladder) & obstructive symptoms.
Independent Medical Trust
Title: PROSTATIC HYPERPLASIA (BPH);
Description:
Objectives: To determine the efficacy of tamsulosin with and without tolterodine in patients having benign prostatic hyperplasia (BPH) with irritative (overactive bladder) symptoms.
Study Design: Randomized clinical trial.
Setting: Department of Urology and Kidney Transplantation, Sheikh Zayed Hospital Lahore.
Period: Six months from July to Dec 2017.
Patients and Methods: Sixty patients of BPH had irritative (overactive bladder) & obstructive presentation were recruited.
Patients were categorized in two groups and were compared for efficacy according to international prostatic symptom scoring while the data analyzed in SPSS 16.
Results: Patients with BPH having irritative (overactive bladder) symptoms, after receiving Tamsulosin with Tolterodine, 76.
60% (23/30) of patients reported symptomatic improvement whereas only 40.
00 % (12/30) of subjects improved with tamsulosine only.
Rate of improvement was observed to be higher in individuals with tamsulosine with tolterodine (Group B) than group A (includes tamsulosin only) with statistical significance) chi-square = 8.
297; p=0.
004).
Conclusion: Efficacy of tamsulosin with tolterodine is higher than tamsulosin alone in subjects with BPH had irritative (overactive bladder) & obstructive symptoms.
Related Results
A deep learning derived prostate zonal volume‐based biomarker from T2‐weighted MRI to distinguish between prostate cancer and benign prostatic hyperplasia
A deep learning derived prostate zonal volume‐based biomarker from T2‐weighted MRI to distinguish between prostate cancer and benign prostatic hyperplasia
Abstract
Background
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) share overlapping characteristics on mag...
Hubungan Diabetes Melitus Tipe II Dengan Kejadian Benigna Prostat Hiperplasia Di Rumah Sakit Pertamina Bintang Amin Bandar Lampung
Hubungan Diabetes Melitus Tipe II Dengan Kejadian Benigna Prostat Hiperplasia Di Rumah Sakit Pertamina Bintang Amin Bandar Lampung
ABSTRACTBenign prostatic hyperplasia (BPH) is a typical histological disorder characterized by the proliferation of prostate cells. Accumulation of cells and gland enlargement is t...
Biochemical and Histopathological evaluation of prostatic tissue under effect of Pterostilbene in benign prostatic hyperplasia rat model
Biochemical and Histopathological evaluation of prostatic tissue under effect of Pterostilbene in benign prostatic hyperplasia rat model
Background: Benign prostatic hyperplasia [BPH] is the urologic condition that affects elderly men the most frequently Benign prostatic hyperplasia. Benign prostatic hyperplasia mus...
Abstract 1163: Chemoprevention of testosterone-induced benign prostatic hyperplasia by hexane fraction from seeds of Annona muricata (soursop) in rats
Abstract 1163: Chemoprevention of testosterone-induced benign prostatic hyperplasia by hexane fraction from seeds of Annona muricata (soursop) in rats
Abstract
Alternative medicine is an extensively recognized therapeutic approach for the management of several diseases. Annona muricata commonly called sour sop is t...
Monotherapy versus combination therapy in the treatment of benign prostatic hyperplasia: A single center study
Monotherapy versus combination therapy in the treatment of benign prostatic hyperplasia: A single center study
Background and objectives: Most benign prostatic hyperplasia patients do not present obvious indicators for surgical intervention, so most of these patients are treated initially w...
Hubungan antara intravesical prostatic protrution, International prostatic symptom score, dan uroflowmetry pada kasus benign prostatic hyperplasia di RSUP Prof. Dr. R. D. Kandou Manado
Hubungan antara intravesical prostatic protrution, International prostatic symptom score, dan uroflowmetry pada kasus benign prostatic hyperplasia di RSUP Prof. Dr. R. D. Kandou Manado
Abstract: Benign prostatic hyperplasia (BPH) is a prostatic gland enlargement due to hyperplasia of its glandular tissue and stroma which can cause low urinary tract symptoms (LUTS...
Doppler Ultrasonography in the Diagnosis of Dogs With Benign Prostatic Hyperplasia and Investigation of the Efficacy of Finasteride in Treatment
Doppler Ultrasonography in the Diagnosis of Dogs With Benign Prostatic Hyperplasia and Investigation of the Efficacy of Finasteride in Treatment
ABSTRACT
Background
Benign prostatic hyperplasia (BPH) is a prevalent condition affecting the prostate gland in adult mal...
TIAM1 signaling drives prostatic budding and branching phenotypes and is a potential therapeutic target for BPH
TIAM1 signaling drives prostatic budding and branching phenotypes and is a potential therapeutic target for BPH
Abstract
Benign prostatic hyperplasia (BPH) is the most prevalent urologic disease in men aged over 50 years. However, the molecular mechanisms that drive BPH patho...

